Health insurance company Clover Health (NASDAQ: CLOV) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 34.1% year on year to $477.6 million. Its non-GAAP loss of $0.02 per share was significantly below analysts’ consensus estimates.

Is now the time to buy CLOV? Find out in our full research report (it’s free).

StockStory’s Take

Clover Health’s second quarter was marked by solid revenue growth and increased membership, but the market reacted negatively, likely due to higher-than-expected non-GAAP losses and operating margin declines. Management pointed to strong execution in its Medicare Advantage business and continued progress with its technology-first care model, notably through the expanded use of the Clover Assistant platform. CEO Andrew Toy acknowledged elevated cost trends in supplemental benefits and Part D expenses, stating the company is closely monitoring these areas, particularly as this is the first year of new IRA-driven changes.

Looking ahead, management is focusing on sustaining membership growth and improving profitability, underpinned by anticipated financial tailwinds from a 4-star payment year in 2026. Clover Health expects that expanded adoption of its technology platform and disciplined cost management will further differentiate its Medicare Advantage offerings. CEO Andrew Toy commented, “We are strategically positioned for accelerated growth and sustained profitability, unlocking Clover’s full potential in the future,” highlighting expectations that new members added in 2025 will mature into higher-margin returning members next year.

Key Insights from Management’s Remarks

Clover Health’s leadership cited rapid membership growth and the scaling impact of its technology-centric care model as core drivers of Q2 performance, while also discussing the operational challenges posed by industry-wide cost increases.

• Membership growth momentum: The company achieved robust Medicare Advantage enrollment gains, with management attributing this to the appeal of its wide-network PPO plan and the effectiveness of its technology-first care model in attracting new members.
• Technology platform impact: Management highlighted the positive influence of the Clover Assistant platform, which uses real-time data and AI to support earlier disease identification and care management. A recently published clinical white paper demonstrated reduced hospitalization rates for COPD patients under providers using this system.
• Cost trends and IRA impact: Leadership acknowledged that elevated utilization of supplemental benefits and higher Part D prescription drug costs, affected by new Inflation Reduction Act (IRA) provisions, negatively impacted profitability. CFO Peter Kuipers emphasized ongoing initiatives to monitor and manage these trends.
• Operating leverage from cost discipline: The company drove improved operating efficiency through company-wide cost initiatives and contract renegotiations, resulting in a lower adjusted SG&A ratio even as the business scaled up.
• Commercialization of technology: Clover Health expanded the reach of its technology by piloting Clover Assistant with independent pharmacies and other risk-bearing entities. Management cited growing interest from external partners as a validation of the platform’s broader healthcare applicability.

Drivers of Future Performance

Management anticipates that future performance will hinge on maintaining membership growth, navigating cost pressures, and leveraging technology to achieve profitability gains.

• 4-star payment year tailwind: The transition to a 4-star payment year in 2026 is expected to provide a meaningful financial boost, as nearly all current members are enrolled in wide-network PPO plans that benefit from increased reimbursement rates.
• Technology adoption and external partnerships: Broader deployment of Clover Assistant, both within the company’s own insurance plan and through partnerships with other healthcare organizations, is projected to improve care quality, support star ratings, and open new avenues for growth.
• Managing industry cost headwinds: Management remains focused on mitigating elevated Part D and supplemental benefit costs, especially those linked to regulatory changes from the IRA. They see diligent trend monitoring and pricing discipline as essential to sustaining profitability.

Catalysts in Upcoming Quarters

In the coming quarters, our team will be tracking (1) the impact of broader Clover Assistant adoption on clinical outcomes and member retention, (2) evidence that cost containment strategies can offset IRA-related pressures on prescription and supplemental benefits, and (3) signs that the upcoming 4-star payment year translates into improved profitability and competitive positioning. We also see the development of new external partnerships as an important marker of strategic progress.

Clover Health currently trades at $2.49, down from $2.84 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.